Solvonis Therapeutics picks SVN-114 as lead PTSD candidate; Ilika PLC ships first commercial solid-state battery electrodes to medical device maker.

Solvonis Therapeutics has selected SVN-114 as its lead candidate for PTSD treatment, following preclinical data showing balanced modulation of serotonin, dopamine, and noradrenaline receptors. The company aims to advance the compound through preclinical development, targeting unmet needs in a condition affecting millions. Meanwhile, UK-based Ilika PLC delivered its first commercial batch of Stereax solid-state battery electrodes to medical device manufacturer Cirtec Medical, marking its first revenue-generating shipment and a key step in commercializing its technology for implantable medical devices. The milestone highlights progress in next-generation battery development for healthcare applications.